AlphAIAlphAI — Financial news for AI agents
pharmaphorum.comOCT 132 min read$SNDX

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

Original reporting
pharmaphorum.com
Published Oct 13, 2026, 9:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 9:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Syndax shares fall as lung fibrosis drug fails trial — source image
Source · pharmaphorum.com
Decision brief

The 30-second read

$SNDXBearishHigh
01

Why it matters

The trial failure is a material negative catalyst for Syndax, likely triggering a sell‑off. Incyte (NASDAQ:INCY), the partner, experiences a modest pullback due to its exposure to the program.

02

Market read

Immediate price impact for SNDX and secondary effect for INCY; broader biotech sentiment may be affected.

03

What to watch

Potential revenue from the approved cGVHD indication could offset the IPF setback.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Syndax Pharma (NASDAQ:SNDX) halted development of axatilimab for idiopathic pulmonary fibrosis after a Phase 2 trial failed to meet its primary endpoint. The company continues development of the drug for chronic graft‑versus‑host disease, a market where it already has an approved product.

Company-level read

Ticker impact

$SNDXBearishHigh confidence
Context

Syndax Pharma announced abandonment of its IPF drug axatilimab after a failed Phase 2 trial, causing a 17% pre‑market drop.

Expected impact

downward pressure as investors price in the failed trial and loss of potential revenue.

Evidence & confidence

Phase 2 failure is material for a biotech; market reacts quickly to trial data.

$INCYBearishMedium confidence
Context

Incyte, partner of Syndax on axatilimab, saw a slight dip after Syndax's trial failure was disclosed.

Expected impact

modest downside as investors assess exposure to the failed program.

Evidence & confidence

Incyte's own pipeline remains intact; impact limited to partnership exposure.

Market effects

Sector

Biotech sector may see broader risk aversion to early‑stage IPF programs.

Regional

US biotech stocks could face short‑term pressure.

Global

Limited to investors tracking clinical trial outcomes.

Counterpoint

What could challenge this read

If Syndax can pivot axatilimab to other indications, the long‑term upside may remain.

Key entities

  • company
    Syndax Pharma

    Biotech firm developing axatilimab for IPF and cGVHD.

  • company
    Incyte

    Partner licensed axatilimab rights; faces minor share dip.

Read at source← All news

StorySyndax Ends Axatilimab Development in IPF After Phase 2 Failure

Also covered by

1 outlet

Related articles

OCT 13
$CMed

Crude Oil Edges Higher; Citigroup Earnings Top Views

Citigroup (NYSE:C) reported Q3 earnings of $2.85 per share, beating estimates. Bumble (NASDAQ:BMBL) surged 56% after a buyout deal. BIO-Key (NASDAQ:BKYI) rose 139% on a government security contract. Fermi (NASDAQ:FRMI) gained 21% on a credit agreement. Pershing Square (NYSE:PS) fell 11% after a downgrade. Cipher Digital (NASDAQ:CIFR) dropped 14% on a convertible notes offering. Syndax (NASDAQ:SNDX) declined 17% after a trial failure. Oil rose 0.4% to $94.13, while gold and silver fell.

benzinga.com7 min
OCT 13
$SNDXMedAI 8/10

Stifel maintains Syndax stock rating after trial failure

Stifel maintained its Buy rating and $40 price target on Syndax Pharmaceuticals (SNDX) after the company's Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed. Syndax will halt further development of the drug for this indication. Stifel noted the setback but kept its positive outlook on Revuforj revenue growth and Niktimvo's potential. SNDX shares fell about 15% post-announcement, trading near their 52-week low.

investing.com2 min
OCT 13
Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

tradingview.com1 min
OCT 13
$SNDXMedAI 8/10

Syndax's Phase 2 MAXPIRe Trial Of Axatilimab Misses Primary Endpoint In IPF; Shares Plunge

Syndax Pharmaceuticals (SNDX) reported that its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) missed the primary endpoint. The trial evaluated the drug's efficacy and safety in 145 patients across 62 sites. Despite the setback, axatilimab was well tolerated, and Syndax will continue its development for chronic graft-versus-host disease (cGVHD).

rttnews.com1 min